PPARγ as a Novel Therapeutic Target in Lung Cancer.
PPARγ as a Novel Therapeutic Target in Lung Cancer.
复制标题
DOI：
10.1155/2016/8972570
复制
发表时间：
2016
期刊：
影响因子：
2.9
通讯作者：
Reddy RC
中科院分区：
文献类型：
--
作者：
Reddy AT;Lakshmi SP;Reddy RC
肺癌是癌症相关死亡的主要原因，超过一半的患者在最初诊断时已处于疾病晚期，因此面临预后不良。这种可怕的情况要求在预防和治疗方面采取新的办法。过氧化物酶体增殖体激活受体γ (PPARγ)是一种配体激活的转录因子，属于核激素受体超家族。PPARγ参与脂肪细胞分化和糖脂稳态是公认的，但现在越来越多的证据表明，PPARγ也可能作为肿瘤抑制因子，抑制肺癌和其他恶性肿瘤的原发性肿瘤和转移的发展。除了具有促分化、抗增殖和促凋亡作用外，PPARγ激动剂已被证明可以阻止癌细胞获得成功转移所必需的迁移和侵袭能力。肿瘤微环境中某些基质金属蛋白酶和细胞外基质蛋白的血管生成和分泌也受到PPARγ的调节。本文对当前文献的回顾强调了PPARγ激动剂作为肺癌新治疗方式的潜力，无论是单独治疗还是与标准细胞毒性化疗联合使用。
Lung cancer is the leading cause of cancer-related death, with more than half the patients having advanced-stage disease at the time of initial diagnosis and thus facing a poor prognosis. This dire situation poses a need for new approaches in prevention and treatment. Peroxisome proliferator-activated receptor γ (PPARγ) is a ligand-activated transcription factor belonging to the nuclear hormone receptor superfamily. Its involvement in adipocyte differentiation and glucose and lipid homeostasis is well-recognized, but accumulating evidence now suggests that PPARγ may also function as a tumor suppressor, inhibiting development of primary tumors and metastases in lung cancer and other malignancies. Besides having prodifferentiation, antiproliferative, and proapoptotic effects, PPARγ agonists have been shown to prevent cancer cells from acquiring the migratory and invasive capabilities essential for successful metastasis. Angiogenesis and secretion of certain matrix metalloproteinases and extracellular matrix proteins within the tumor microenvironment are also regulated by PPARγ. This review of the current literature highlights the potential of PPARγ agonists as novel therapeutic modalities in lung cancer, either as monotherapy or in combination with standard cytotoxic chemotherapy.
登录
查看更多内容
DOI：
10.6004/jnccn.2013.0011
发表时间：
2013-01-01
期刊：
Journal of the National Comprehensive Cancer Network : JNCCN
影响因子：
--
作者：
Kalemkerian GP;Akerley W;Bogner P;Borghaei H;Chow LQ;Downey RJ;Gandhi L;Ganti AK;Govindan R;Grecula JC;Hayman J;Heist RS;Horn L;Jahan T;Koczywas M;Loo BW Jr;Merritt RE;Moran CA;Niell HB;O'Malley J;Patel JD;Ready N;Rudin CM;Williams CC Jr;Gregory K;Hughes M;National Comprehensive Cancer Network
通讯作者：
National Comprehensive Cancer Network
DOI：
10.1097/jto.0b013e3181ce3afd
发表时间：
2010-04
期刊：
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
影响因子：
--
作者：
Jeon HS;Jen J
通讯作者：
Jen J
影响因子：
8
作者：
Bren-Mattison, Y;Van Putten, V;Nemenoff, RA
通讯作者：
Nemenoff, RA
影响因子：
45.3
作者：
Govindarajan, Rangaswamy;Ratnasinghe, Luke;Lang, Nicholas P.
通讯作者：
Lang, Nicholas P.
影响因子：
50.3
作者：
Girnun, Geoffrey D.;Naseri, Elnaz;Spiegelman, Bruce M.
通讯作者：
Spiegelman, Bruce M.